



Market Announcement

2 February 2021

MGC Pharmaceuticals Limited (ASX:MXC) – Trading Halt

Description

The securities of MGC Pharmaceuticals Limited ('MXC') will be placed in trading halt at the request of MXC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 4 February 2021 or when the announcement is released to the market.

Issued by

Daniel Nicholson

Adviser, Listings Compliance (Perth)

2 February 2021

Australian Securities Exchange
Level 40, Central Park
152-158 St Georges Tce
Perth WA 6000

Via email: tradinghaltperth@asx.com.au

Dear Sir/Madam,

The Directors of MGC Pharmaceuticals Ltd (the “Company”) request that the Company’s securities be placed in a voluntary trading halt effective from the commencement of trading on Tuesday, 2 February 2021, and provides the following information in relation to ASX Listing Rule 17.1:

- the Company intends to make two announcements to the market in relation to:
 - Proposed Dual Listing on the London Stock Exchange; and
 - an Investor Presentation for the purposes of undertaking Placement to sophisticated and institutional investors in the UK;
- the Company wishes the trading halt to last until the commencement of normal trading on Thursday, 4 February 2021 so as to allow time to:
 - confirm the details relating to the capital raising and secure commitments for the proposed capital raising;

The Company requests that the trading halt end on the earlier of the commencement of normal trading on 4 February 2021, or when the announcement referred to above is released to the market.

The Company is not aware of any reason why the trading halt should not be granted, nor of any other information necessary to inform the market about the trading halt, and the Company confirms that the request for a trading halt is material.

Yours faithfully



Narelle Warren
Company Secretary